FDA study finds Visian ICL offers good long-term BSCVA

Article

Over a five-year follow-up period the Visian implantable collamer lens (ICL) (STAAR Surgical) maintains a good level of best spectacle corrected visual acuity (BSCVA).

Over a five-year follow-up period the Visian implantable collamer lens (ICL) (STAAR Surgical) maintains a good level of best spectacle corrected visual acuity (BSCVA), according to results from the US multicentre FDA study, as reported by John Vukich of Madison, Wisconsin, USA.

A total of 248 patients implanted with the Visian ICL have been followed for four yeas and 335 have been followed for >5 years. The average preoperative myopia was -10.06 D.

At five years, 52.7% of eyes with a preoperative BSCVA of 20/20 or better achieved a UCVA of 20/20 or better and 91.2% achieved a UCVA of 20/40 or better. Over the five-year period, seven patients (1.3%) developed clinically significant anterior subcapsular cataracts, each requiring extraction. No other complications were reported.

The results of this FDA study indicate that the Visian ICL is safe and effective in maintaining BSCVA over a five-year period.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.